anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This randomized controlled trial will be conducted in Clinical Hospital Center Sestre milosrdnice and University of Zagreb School of medicine. Patients will be randomized after completing the EAT-26 questionnaire (1:1), in group with disordered eating behaviour (n=30) if participants scored \>20 points, and group without disordered eating behaviour (n=30) if participants scored ≤20 points. Group of patients with disordered eating behaviour will be further randomized whether participants will receive semaglutide (n=15) with standard care or if participants will be treated with standard care (n=15). The investigators will evaluate baseline EAT-26 score, GLP-1 and GIP blood levels in a mixed meal test, anthropometric measurements (weight, BMI, waist circumference), biochemical parameters (complete blood count, glucose, insulin, c-peptide, HbA1c, urea, creatinine, uric acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), international normalized ratio (INR), albumin, serum lipid levels (cholesterol. HDL, LDL, triglyceride), C reactive protein (CRP), urine sediment and their changes at the end of the trial (except mixed meal test). Also, through 14 days at the beginning and 14 days before the end of the trial, patients will keep a food diary and have intermittently scanned continuous glucose monitor (FreeStyle Libre Pro CGM device, Abbott).

A factor analysis of EAT-26 scores will be conducted to form 3 (expected) latent variables (components). To assess the effect on dietary habits, the difference in EAT-26 total score and latent variables between subjects randomized to semaglutide and control subjects (randomized to standard care) will be assessed after 3 months of treatment. The data will be analysed in a general linear model, with basal covariates: age, sex, BMI and score at the beginning of treatment. In the same way, the effect of semaglutide on GLP1 concentrations (basal covariate: basal concentration next to the location of the EAT-26 score) will be evaluated, separately for the condition before and after the mixed meal test. GLP-1 and GIP concentrations will be compared between subjects with ("exposed") and without (control) eating disorders, in a generalized linear model for repeated measurements (GLP-1 concentration before and after mixed meal test) with fixed covariates: age, sex, BMI, time ( before or after mixed meal test) and exposure\*time interactions. Type I (α) error=0.05.
Participants with no genetic variation in their VDR, GC and CYP2R1 genes that would increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group is a control against the medium and high-risk intervention groups.
The present invention relates to a medicament for treating oral ulcer and pharyngolaryngitis. The medicament comprises the following raw materials according to the portions by weight: 1 to 12 portions of natural indigo, 2 to 60 portions of honeysuckle flower and 0.1 to 2 portions of borneol. Natural indigo and honeysuckle flower are added with 60% to 80% of ethanol, refluxed and extracted, and filter liquor of the natural indigo and the honeysuckle flower are concentrated into paste and added with borneol to prepare the medicament. The medicament has the functions of clearing heat, removing toxicity, relieving inflammation, alleviating itch and regenerating tissue to heal wound, and has conspicuous stypticity function on the wound surface of the oral mucosa. The medicament can treat both the symptoms and root causes. The medicament has the advantages of small dosage, good mouth feeling, no toxic substance and high safety. The medicament can effectively treat oral ulcer, halitosis and pharyngolaryngitis, and can be widely used by male, female, the old, the young and the weak.
The invention relates to a method for extraction and preparation of ganoderma lucidum allpmelanin and a use of the ganoderma lucidum allpmelanin. The ganoderma lucidum allpmelanin is extracted from ganoderma lucidum and is black powder. The ganoderma lucidum allpmelanin contains 54.4% of C, 4.2% of H, 2.9% of N, and 1.9% of S, and is catechol botanical allpmelanin. Polyphenol substances are transformed into a hydroxyquinone under the action of polyphenol oxidase and phenol hydroxylase and then form the catechol botanical allpmelanin through polymerization. The preparation method comprises the following steps of carrying out degreasing of ganoderma lucidum by ethanol to obtain a degreased dry product, carrying out extraction of the degreased dry product by an acid solution, filtering to remove extract obtained the acid extraction, collecting filter residues, carrying out extraction of the filter residues by an alkali solution, filtering, collecting extract obtained by the alkali extraction, carrying out microfiltration of the extract obtained by the alkali extraction to remove insoluble substances, carrying out nanofiltration desalination, drying to obtain allpmelanin crude extract, putting the allpmelanin crude extract into an acid solution, carrying out hydrolysis, and carrying out separation to obtain the ganoderma lucidum allpmelanin. The method provided by the invention is simple, can be realized easily, is suitable for industrial production and does not produce environmental pollution. The ganoderma lucidum allpmelanin obtained by the method can be utilized for treating and preventing diabetes mellitus and has good economic benefits.
Active tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator. An anodal electrode is placed above the primary motor cortex, M1, while a cathode is placed above the contralateral supraorbital area.
OBJECTIVES: The recurrence of underlying diseases remains a major cause of graft failure after liver transplant. This study aimed to identify factors associated with the recurrence of underlying diseases and investigate the incidence of these factors and recurrence at the main liver transplant center in Iran.
MATERIALS AND METHODS: We included adult liver transplant recipients followed at Shiraz Transplant Center between 2011 and 2018 with a confirmed diagnosis of recurrence of underlying disease in our study. We reviewed medical records and extracted data on demographic characteristics, clinical and paraclinical features, medication use, and current status. We used a systematic random sampling method to select a control group of 95 transplant recipients who did not have recurrence. Of 3022 total transplant recipients, 76 recipients experienced a recurrence of their underlying disease.
RESULTS: Model for End-Stage Liver Disease score, underlying disease, recipient blood group, donor sex, donor blood group, and rejection frequency were significantly different between study groups with and without recurrence of underlying diseases. Liver transplant recipients with recurrence had lower mean Model for End-Stage Liver Disease score. Recipients with recurrence also had higher rate of drug consumption (eg, prednisolone, tacrolimus, mycophenolate mofetil, sirolimus). Regression analysis showed that donor sex and rejection frequency had an effect on disease recurrence. Death occurred more frequently in liver transplant recipients with recurrence than in the control group (39.5% vs 26.3%), butthe difference was not significant.
CONCLUSIONS: Donor sex and acute rejection frequency are independent factors predictive of the recurrence of underlying disease. Modifying risk factors can help minimize the recurrence of underlying diseases after liver transplant.
Patients in the monotherapy arm will be treated with olaparib until the 21st -28th day depending on the day of surgery, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
OBJECTIVE: Treatment of bipolar disorder (BD) involves complexities especially when patients come with significant sensitivity to various psychotropic medications and comorbidities. The following cases aim to recapitulate and discuss some of such situations.
CASES: Case 1: A 36-year-old man with intellectual development disorder and BD experienced catatonia, seizures, and hyperammonemia following valproate administration. Treatment involved electroconvulsive therapy (ECT) and a tailored medication regimen, ultimately leading to stability. Case 2: A 63-year-old man with long-standing BD exhibited resistance to lithium and valproate of late, having co-existing essential tremors and cerebellar atrophy. Multiple medication trials led to side effects, requiring ECT for symptom improvement, followed by a carefully adjusted maintenance regimen.
CONCLUSION: Medication side effects can pose major challenges in treatment of BD. Comprehensive evaluation and monitoring are essential. ECT can prove valuable in such cases. There is pressing need to develop more safer treatment alternatives, especially considering the progressively ageing society.
The study will involve 41 people who regularly seek treatment at clinics. Participants must be in generally good health and be older than eighteen. must have at least 20 teeth in an occlusion and maintain appropriate dental hygiene. They have to be treated for a minimum of four non-cancerous cervical lesions in their mouths.Four non-carious cervical lesions from patients will be separated into four groups, and adhesive material will be applied to the lesions in each group using different procedures. Evaluation will be performed based on World Dental Federation (FDI) criteria after initial, ½, 1, 2, 3, 4, and 5 years. In each evaluation period, esthetic (surface gloss, surface coloration, marginal discoloration, color match and translucency, esthetic anatomic form), functional (fracture and retention, marginal adaptation), and biologic criteria (postoperative sensitivity and vitality, caries recurrence) will be evaluated.
To prepare a mixture of sulphurised, polyunsaturated fatty acids or triglycerides synthesised from such fatty acids, the same are mixed with an excess of sublimed sulphur and then kept with heating for an adequately long time with stirring at 90 to 130 DEG C to carry out the sulphur uptake. The mixture is then cooled to room temperature. Unreacted sulphur is either separated off or left in the liquid mixture. If the mixture is allowed to stand without separation of the unreacted sulphur, it additionally takes up further sulphur. Sulphurised, polyunsaturated product mixtures result which contain from 0.1 up to 2.5% by weight of sulphur. The polyunsaturated oil employed can be sesame oil. The sulphurised products of this type are used in capsules for the temporary interruption of the need for alcohol.
A method for neural regeneration is provided at specific situses that include the inner ear and retina, where Ganglion cells respond to the method through at least stimulation of such cells. As a result, the method provides for reversing clinical conditions associated with the nerve degradation or disease. Specific clinical conditions reversed at least in part through nerve regeneration include hearing loss, tinnitus, and a host of neurotrophic retinopathies, diabetes, Norrie disease, and others. Nerve regeneration is accomplished with a protein that is a truncated synthetic polypeptide related to native norrin protein. Truncated norrin proteins have a longer half-life in the situs than native norrin proteins. A version of the truncated norrin protein lacks a cleavage site for a subject protease enzyme that cleaves native norrin proteins and thereby shortens the useful life of the therapeutic protein.
Creative Engagement Intervention participants will receive 4-8 art sessions over 3-5 weeks, depending on length of inpatient stay. Sessions will be delivered as 1:1 sessions with the artist lasting up to one hour (depending on patient fatigue levels) and group sessions, with up to 5 participants, lasting up to two hours (depending on patient fatigue levels). Participant with receive one group and one individual session per week of inpatient stay. The sessions will cover 5 activity stages of the intervention, taking the participant through a progressive artwork development process. Participants will explore basic visual art materials and processes and progress to creating artworks with a personal context that they have directed and controlled.
There is no clear guidance on the efficacy of stone follow-up. NICE have been unable to make recommendations with current published evidence. The aim of this study was to understand the patient journey resulting in surgical intervention, and whether traditional stone follow-up is effective. A retrospective review of patients undergoing ureteroscopy (URS) or percutaneous nephrolithotomy (PCNL) over a 3 year period identified 471 patients who underwent these procedures to treat stone disease. Records were interrogated for the following: symptoms, mechanism of booking, reason for intervention, stone size, stone location, risk factors and previous follow-up. Of 471 patients who underwent intervention, 168 were booked from stone clinic follow-up (36%). Of these, 96% were symptomatic and 4% were asymptomatic. When risk factors were removed, this figure was reduced to 1%. Sepsis rate for emergency admissions differs between those followed up (13%) versus new presentations (19)%. There was no statistically significant difference in the outpatient imaging frequency between patients booked from an emergency admission (80% having imaging every 6 months) and those from the clinic (82%). Our Hospital provides on average 650 stone clinic appointments a year with a cost of £93,000. Given the low rate of intervention in patients with asymptomatic renal stones, a symptomatic, direct-access emergency stone clinic could be a better model of care and use of NHS resources. Urgent research is required in this area to further assess if this is the case.
Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received an Omron pedometer and learned to monitor walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks, in-group, to walk at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
Thirty (30) consecutive patients indicated for treatment of prostate cancer with HIFU (FocalOneR, Edap TMS, France) will be selected to the manometry study before the treatment together with the application of specific questionnaires (Cleveland Clinic Incontinence Score-CCIS, Fecal Incontinence Quality of Life Score-FIQLS, and Rome IV for functional constipation. This evaluaton will be conducted again after the treatment.
Patient with established chronic heart failure which after a period of "stable" HF have experienced an hospital admission with necessity of iv. diuretics or urgent visit needing iv. diuretics. Patients can be included in inpatient / admitted setting or outpatient setting where drug changes during admission (GDMT uptitration) can be recorded. The index event of hospitalisation must be within 6 months prior to inclusion in the registry (retrospective).
Cyclosporine A (CsA) is an immunosuppressive drug, used in organ transplantations. Oxidative stress, inflammation and renin-angiotensin system (RAS) activation play an important role in CsA-toxicity. Glycine (Gly) has antioxidant and anti-inflammatory effects. In this study, Gly was investigated for its protective role against CsA-induced toxicity. CsA (20 mg/kg/day; subcutaneously) was administered to rats along with Gly injection (250 or 1000 mg/kg; intraperitoneally) for 21 days. Renal function markers [serum urea and creatinine and urinary protein and kidney injury molecule levels and creatinine clearance values] together with histopathological examinations were performed. Oxidative stress (reactive oxygen species, thiobarbutiric acid reactive substances, advanced oxidation products of protein, glutathione, ferric reducing anti-oxidant power and 4-hydroxynonenal levels), and inflammation (myeloperoxidase activity) were determined in kidney tissue. The RAS system [angiotensin II (Ang II) levels, and mRNA expressions of angiotensin converting enzyme (ACE), angiotensin II type-I receptor (AT1R)] and NADPH-oxidase 4 (NOX4) were measured in kidney and aorta. CsA caused significant disturbances in renal function markers, increases in oxidative stress and inflammation parameters and renal damage. Serum angiotensin II levels and mRNA expressions of ACE, AT1R and NOX4 elevated in the aorta and kidney of CsA-rats. Gly, especially its high-dose, alleviated renal function markers, oxidative stress, inflammation and renal damage in CsA-rats. Moreover, serum Ang II levels and mRNA expressions of ACE, AT1R and NOX4 decreased significantly in aorta and kidney in CsA-rats due to Gly treatment. Our results indicate that Gly may be useful for the prevention of CsA-induced renal and vascular toxicity.
Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs. The 6-8 injections contained \~ 60 × 10\^6 dendritic cells. Following evaluation after the first dose, participants received additional injections as described for the randomized Cvac group below.
Patients 65 years old and older will receive a pre-consultation screening questionnaire by phone prior to their virtual or in-person visit. A summary report based on the results of the questionnaire will be placed in the patient electronic chart for use by the clinician at the time of visit.
Generator for gallium-68 daughter nuclide, comprises germanium-68 parent nuclide, which is specifically immobilized on a carrier by trihydroxyphenyl groups or dihydroxyphenyl groups. The parent nuclide immobilized on the carrier is continuously decayed with a half-life of 270.82 days by electron capture, to obtain gallium-68 daughter nuclide. The trihydroxyphenyl groups or the dihydroxyphenyl groups are covalently bonded to the carrier material by a linker comprising esters with 2-20C, alkylene with 2-20C, phenyl thiourea, amines with 2-20C, melamine or trihydroxyphenyl alkoxysilane. Generator for gallium-68 daughter nuclide, comprises germanium-68 parent nuclide, which is specifically immobilized on a carrier by trihydroxyphenyl groups or dihydroxyphenyl groups. The parent nuclide immobilized on the carrier is continuously decayed with a half-life of 270.82 days by electron capture, to obtain gallium-68 daughter nuclide. The trihydroxyphenyl groups or the dihydroxyphenyl groups are covalently bonded to the carrier material by a linker comprising esters with 2-20C, alkylene with 2-20C, phenyl thiourea, amines with 2-20C, melamine or trihydroxyphenyl alkoxysilane, preferably 1,2,3-trihydroxyphenyl triethoxysilane, 1,2,3-trihydroxyphenyl diethoxysilane, 1,2,3-trihydroxyphenyl ethoxysilane, 1,2,3-trihydroxyphenyl tripropoxysilane, 1,2,3-trihydroxyphenyl chlorosilane, epichlorohydrin, isothiocyanates or thiols.
PURPOSE: To obtain a total infusion stable for a long period of time, having excellent nutrient effect, containing an amino acid, a saccharide and a water-soluble vitamin B. CONSTITUTION: A water-soluble vitamin (e.g. vitamin B1 ) is added to either of an amino acid infusion containing no sulfite ion or a saccharide infusion, an electrolyte (e.g. Na) is added to the amino acid infusion or the saccharide infusion or both and the infusions are adjusted to proper pH by using an acid or a base. The infusion mixed with the water-soluble vitamin is adjusted to pH2 to pH4 and the other infusion is adjusted to pH5 to pH8 and both the infusions are adjusted to pH5 to pH6 in blending. The prepared amino acid infusion and the saccharide infusion are filtered, the two solutions are partially added to a container to make two solutions into one solution, thermally sterilized and sealed with a deoxidation agent to give a total agent.  The total infusion does not require complicated operation which occurs in conventional administration of an infusion with a water-soluble vitamin B and is administered without causing contamination with a microorganism and fine particles.
The inflammatory bowel disease (IBD) subtype, Crohn's disease (CD) is a chronic and relapsing inflammatory disorder of the gastrointestinal tract. Although the precise etiology of IBD is not known, evidence suggests that environmental factors, including diet, contribute to its pathogenesis. A soy-based diet has been demonstrated to have numerous health benefits. This single-center open-label study will compare the effectiveness of a soy-based diet or an identical diet without soy to change the gut microbiota composition and fecal butyrate concentration to that of baseline (pre-diet) in patients with CD (remission or active disease) and healthy control subjects without CD. Participants will follow either a soy-based diet or an identical diet without soy to which they will be randomized for 7 days. No data collection or other study procedures will take place until the potential participant provides written informed consent to participate in the research study. The informed consent, screening, enrollment, and baseline data collection which make up visit 1 can occur on the same day or be completed across several days.
There is only one arm as all patients undergo the same intervention. Subjects with clinical features/symptoms of a stroke (hemorrhagic and non-hemorrhagic stroke patients) will be enrolled. All patients will undergo first a non-contrast MDCT scan and then a non-contrast syngo DynaCT Sine Spin head scan within a maximum timespan of 4 hours between both scans. Only patients in which no invasive procedure in between is planned can be enrolled.
The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has one or more monomers that have a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacteria, bacterial proteins, viruses, viral proteins, cancer cells, and proteins or toxins produced therefrom or from other sources such as snakes, insects, plants, etc. In particular, the present invention includes methods and systems for binding agents having one or more monomers that are specific to neurotoxins that cause botulism.